For decades, rare disease research was treated as noble but incidental, peripheral to the pharmaceutical industry’s market-driven priorities. While blockbuster drug discovery focused on the "average patient" and the pursuit of high-volume, high-profit medicines, the rare disease community worked under very different conditions: small patient cohorts, limited data, and diseases whose root causes were often poorly understood.
The “average patient,” however, was never truly representative.
For much of modern medical research, clinical evidence was built primarily on studies of young white male participants, leaving women, older adults, and ethnically diverse populations severely underrepresented. As a result, many patients have long received treatments that were never fully tested in people like them. Researchers studying rare diseases, by necessity, learned how to account for individuality early because there was never a large or homogenous population on which to rely.
As our understanding of molecular biology has deepened, the very idea of a single average patient has begun to break down across medicine. Conditions once labeled as common, including diabetes, hypertension, cancer, and neurological disorders, are increasingly understood as genetically and molecularly distinct subtypes. In oncology and neurology, in particular, diseases are now defined by biomarkers and mutations, rather than by clinical presentations alone. The emergence of gene and cell therapies is further accelerating this shift, transforming general medicine into specialized biological engineering.
As a result, many areas of biomedical research now face constraints that rare disease researchers have navigated for decades. Small populations, incomplete datasets, and complex biology are no longer the exception, and the strategies that rare disease researchers have spent years perfecting could provide the blueprint for the future of medicine.
Necessity Drives Innovation in Rare Disease Research
Traditional drug development was built around statistical averages, often requiring thousands of patients to demonstrate clinical benefit over placebo. But for therapies targeting a specific genetic mutation found in only a small fraction of patients, such trials are simply impossible. Rare disease researchers have long faced this challenge and adapted their approaches accordingly.
Novel applications of methods like Bayesian statistical models allow researchers to extract meaningful signals from limited and noisy data. Rather than relying on broad averages across large groups, these approaches utilize longitudinal, high-resolution data from individual patients. The result is that researchers collect rich clinical, molecular, and functional data from each individual over time, and each patient becomes a critical source of insight rather than a single data point.
Rare disease research has also served as a testing ground for innovation in clinical trial design and regulation. Frameworks such as basket trials (studies that test a single therapy across multiple diseases sharing a common molecular feature), umbrella trials (studies that evaluate multiple targeted therapies within a single disease based on different biomarkers), and N‑of‑1 studies (rigorous crossover experiments conducted within a single patient to determine their individual treatment response) were pioneered to address constraints in the orphan disease space. These approaches are now being integrated into broader disease areas.
Regulatory pathways have also evolved alongside these methods. Building on the 21st Century Cures Act, which enabled the use of real-world evidence to support regulatory decisions, the FDA introduced the Rare Disease Evidence Principles in 2025. These principles signal growing flexibility around approaches like external control arms and real-world evidence that may increasingly extend beyond rare diseases when traditional trials are infeasible or unethical.
Similarly, the Accelerated Approval Program, which allows earlier approval of drugs for serious or life-threatening diseases, was originally shaped by rare disease needs and is now widely used in oncology. As we move toward increasingly personalized interventions, replacing placebo arms with a patient’s own clinical history or a well-constructed synthetic control is becoming both a practical and ethical necessity. Rare disease researchers have already done much of the heavy lifting required to prove to regulators that these methods are scientifically sound and can meet regulatory standards. In doing so, the rare disease community is helping to de-risk the complicated process of drug approval for everyone else.
Radical Collaboration and the Patient-Led Research Revolution
In much of the pharmaceutical industry, data is a proprietary asset closely guarded to ensure a competitive advantage. In the rare disease world, silos are a death sentence for the development of new therapies. When only a few hundred or even a few dozen patients with a specific disease exist worldwide, no single institution can generate sufficient data or evidence alone. This reality has forced rare disease researchers to embrace a culture of early and open data sharing. They have established pre-competitive consortia, international patient registries, standardized biobanks, and shared research infrastructure. By working together, they have proven that collaboration is not an idealistic choice—it’s a scientific necessity.
Perhaps the most profound lesson we can learn from the rare disease community comes from the changing role of patients and their families. In traditional clinical trials, the patient was a subject, a passive recipient of a rigid protocol. In rare disease research, patients and caregivers are often active drivers of advancement. They raise funding for basic research, establish natural history studies, help recruit participants, and work with scientists and clinicians to define outcomes that are most relevant to their quality of life.
By integrating patient experience into the trial design from the outset, rare disease studies can produce therapies that are more relevant to patients’ needs and more likely to succeed in the real world than treatments developed without meaningful patient input. This patient-centered approach is what is needed to address long-standing gaps in medical evidence, particularly for populations that have been failed by the medical system due to underrepresentation in clinical research.
Solving for One to Solve for All
The deeper we look into human biology, the more individual variation we uncover. In a sense, we are all becoming "rare" because we are all unique. Rare disease research is not a marginal endeavor; it is an early laboratory for the challenges that increasingly define modern medicine. It is where researchers are learning how to work with biological complexity, how to extract insight from limited data, how to learn from every patient individually, and how to collaborate toward a common goal.
If we want to know what the future of medicine looks like, we should not look to the blockbuster drugs of the past, we should look to the rare disease pioneers of the present. They are not just solving for a few rare patients; they are modeling how to build a research system that solves for all.
